In silico carborane docking to proteins and potential drug targets

Journal of Chemical Information and Modeling

Volumn 51, Issue 8, 2011, Pages 1882-1896

  Calvaresi, Matteo ^a   Zerbetto, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES; BORON;

BORON NEUTRON CAPTURE THERAPY; CARBORANE DERIVATIVES; METALLO-PROTEASE; PHARMACOLOGICAL ACTIVITY; POTENTIAL DRUG TARGETS; PROTEIN DATA BANK; PROTEIN STRUCTURES; TARGETS OF INTEREST;

PROTEINS;

BORANE DERIVATIVE; BORON; DRUG; ENZYME INHIBITOR; LIGAND; METALLOPROTEINASE;

ARTICLE; BINDING SITE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; NEUTRON CAPTURE THERAPY; PATHOLOGY; PROTEIN BINDING; PROTEIN DATABASE; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; BORANES; BORON; BORON NEUTRON CAPTURE THERAPY; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DATABASES, PROTEIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; LIGANDS; METALLOPROTEASES; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80052003702     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci200216z     Document Type: Article

References (106)

1. Heying, T. L.; Ager, J. W.; Clark, S. L.; Mangold, D. J.; Goldstein, H. L.; Hillman, M.; Polak, R. J.; Szymanski, J. W. A new series of organoboranes. I. Carboranes from the reaction of decaborane with acetylenic compounds Inorg. Chem. 1963, 2, 1089-1092
2. Hunter, P. Not boring at all EMBO Rep, 2009, 10, 125-128
3. Valliant, J. F.; Guenther, K. J.; King, A. S.; Morel, P.; Schaffer, P.; Sogbein, O. O.; Stephenson, K. A. The medicinal chemistry of carboranes Coord. Chem. Rev. 2002, 232, 173-230
4. Sivaev, I. B.; Bregadze, V. V. Polyhedral boranes for medical applications: current status and perspectives Eur. J. Inorg. Chem. 2009, 11, 1433-1450
5. Armstrong, A. F.; Valliant, J. F. The bioinorganic and medicinal chemistry of carboranes: From new drug discovery to molecular imaging and therapy Dalton Trans. 2007, 38, 4240-4251 (Pubitemid 47485645)
6. Lesnikowski, Z. J. Boron units as pharmacophores: New applications and opportunities of boron cluster chemistry Collect. Czech. Chem. Commun. 2007, 72, 1646-1658
7. 12 and their derivatives Chem. Rev. 1992, 92, 209-223
8. Hawthorne, M. F. The role of chemistry in the development of boron neutron capture therapy of cancer Angew. Chem., Int. Ed. 1993, 92, 209-233
9. Barth, R. F.; Coderre, J. A.; Vicente, M. G. H.; Blue, T. E. Boron neutron capture therapy of cancer: Current status and future prospects Clin. Cancer Res. 2005, 11, 3987-4002 (Pubitemid 40791562)
10. Kruger, P. G. Some biological effects of nuclear disintegration products on neoplastic tissue Proc. Natl. Acad. Sci. U.S.A. 1940, 26, 181-192
11. Hawthorne, M. F.; Maderna, A. Applications of radiolabeled boron clusters to the diagnosis and treatment of cancer Chem. Rev. 1999, 99, 3421-3434 (Pubitemid 129589124)
12. Tolmachev, V.; Koziorowski, J.; Sivaev, I.; Lundqvist, H.; Carlsson, J.; Orlova, A.; Gedda, L.; Olsson, P.; Sjoeberg, S.; Sundin, A. Closo -Dodecaborate(2-) as a Linker for Iodination of Macromolecules. Aspects on Conjugation Chemistry and Biodistribution Bioconjugate Chem. 1999, 10, 338-345 (Pubitemid 29243313)
13. Wilbur, D. S.; Chyan, M. K.; Hamlin, D. K.; Vessella, R. L.; Wedge, T. J.; Hawthorne, M. F. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination Bioconjugate Chem. 2007, 18, 1226-1240 (Pubitemid 47134664)
14. Kabalka, G. W.; Yao, M.-L. The synthesis and use of boronated amino acids for boron neutron capture therapy Anti-Cancer Agents Med. Chem. 2006, 6, 11-125
15. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Yamaguchi, M.; Fukasawa, M.; Shudo, K. Potent estrogenic agonists bearing dicarba- closo -dodecaborane as a hydrophobic pharmacophore J. Med. Chem. 1999, 42, 1501-1504 (Pubitemid 29226721)
16. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Fukasawa, H.; Miyaura, C.; Inada, M.; Kubo, A.; Itai, A. Potent estrogen agonists based on carborane as a hydrophobic skeletal structure. A new medicinal application of boron clusters Chem. Biol. 2001, 8, 341-355 (Pubitemid 32442489)
17. Endo, Y.; Yoshimi, T.; Ohta, K.; Suzuki, T.; Ohta, S. Potent estrogen receptor ligands based on bisphenols with a globular hydrophobic core J. Med. Chem. 2005, 48, 3941-3944 (Pubitemid 40800603)
18. Ohta, K.; Ogawa, T.; Suzuki, T.; Ohta, S.; Endo, Y. Novel estrogen receptor (ER) modulators: Carbamate and thiocarbamate derivatives with m-carborane bisphenol structure Bioorg. Med. Chem. 2009, 17, 7958-7963
19. Causey, P. W.; Besanger, T. R.; Valliant, J. F. Synthesis and screening of mono- and di-aryl technetium and rhenium metallocarboranes. A new class of probes for the estrogen receptor J. Med. Chem. 2008, 51, 2833-2844 (Pubitemid 351620804)
20. Goto, T.; Ohta, K.; Suzuki, T.; Ohta, S.; Endo, Y. Design and synthesis of novel androgen receptor antagonists with sterically bulky icosahedral carboranes Bioorg. Med. Chem. 2005, 13, 6414-6424 (Pubitemid 41539306)
21. Fujii, S.; Hashimoto, Y.; Suzuki, T.; Ohta, S.; Endo, Y. A new class of androgen receptor antagonists bearing carborane in place of a steroidal skeleton Bioorg. Med. Chem. Lett. 2005, 15, 227-230 (Pubitemid 39575815)
22. Fujii, S.; Goto, T.; Ohta, K.; Hashimoto, Y.; Suzuki, T.; Ohta, S.; Endo, Y. Potent androgen antagonists based on carborane as a hydrophobic core structure J. Med. Chem. 2005, 48, 4654-4662 (Pubitemid 40993424)
23. Goto, T.; Ohta, K.; Fujii, S.; Ohta, S.; Endo, Y. Design and synthesis of androgen receptor full antagonists bearing a p -carborane cage: Promising ligands for anti-androgen withdrawal syndrome J. Med. Chem. 2010, 53, 4917-4926
24. Endo, Y.; Iijima, T.; Yaguchi, K.; Kawachi, E.; Inoue, N.; Kagechika, H.; Kubo, A.; Itai, A. Structure-activity study of retinoid agonists bearing substituted dicarba- closo -dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei Bioorg. Med. Chem. Lett. 2001, 11, 1307-1311 (Pubitemid 32434358)
25. Endo, Y.; Yoshimi, T.; Kimura, K.; Itai, A. Protein kinase C modulators bearing dicarba- closo -dodecaborane as a hydrophobic pharmacophore Bioorg. Med. Chem. Lett. 1999, 9, 2561-2564 (Pubitemid 29435538)
26. Al-Madhoun, A. S.; Johnsamuel, J.; Yan, J. H.; Ji, W. H.; Wang, J. H.; Zhuo, J. C.; Lunato, A. J.; Woollard, J. E.; Hawk, A. E.; Cosquer, G. Y.; Blue, T. E.; Eriksson, S.; Tjarks, W. Synthesis of a small library of 3-(carboranylalkyl)thymidines and their biological evaluation as substrates for human thymidine kinases 1 and 2 J. Med. Chem. 2002, 45, 4018-4028 (Pubitemid 35024303)
27. Lunato, A. J.; Wang, J. H.; Woollard, J. E.; Anisuzzaman, A. K. M.; Ji, W. H.; Rong, F. G.; Ikeda, S.; Soloway, A. H.; Eriksson, S.; Ives, D. H.; Blue, T. E.; Tjarks, W. Synthesis of 5-(carboranylalkylmercapto)-2′- deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2 J. Med. Chem. 1999, 42, 3378-3389 (Pubitemid 29409726)
28. Tsuji, M.; Koiso, Y.; Takahashi, H.; Hashimoto, Y.; Endo, Y. Modulators of tumor necrosis factor alpha production bearing dicarba- closo -dodecaborane as a hydrophobic pharmacophore Biol. Pharm. Bull. 2000, 23, 513-516 (Pubitemid 30241828)
29. Julius, R. L.; Farha, O. K.; Chiang, J.; Perry, L. J.; Hawthorne, M. F. Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 4808-4813 (Pubitemid 47186132)
30. Scholz, M.; Kaluderovic, G. N.; Kommera, H.; Paschke, R.; Will, J.; Sheldrick, W. S.; Hey-Hawkins, E. Carbaboranes as pharmacophores: Similarities and differences between aspirin and asborin Eur. J. Med. Chem. 2011, 46, 1131-1139
31. Page, M. F. Z.; Jalisatgi, S. S.; Maderna, A.; Hawthorne, M. F. Design and synthesis of a candidate α-human thrombin irreversible inhibitor containing a hydrophobic carborane pharmacophore Synthesis 2008, 4, 555-563
32. Reynolds, R. C.; Campbell, S. R.; Fairchild, R. G.; Kisliuk, R. L.; Micca, P. L.; Queener, S. F.; Riordan, J. M.; Sedwick, W. D.; Waud, W. R.; Leung, A. K. W.; Dixon, R. W.; Suling, W. J.; Borhani, D. W. Novel boron-containing, nonclassical antifolates: Synthesis and preliminary biological and structural evaluation J. Med. Chem. 2007, 50, 3283-3289 (Pubitemid 47065977)
33. Beer, M. L.; Lemon, J.; Valliant, J. F. Preparation and evaluation of carborane analogues of tamoxifen J. Med. Chem. 2010, 53, 8012-8020
34. Cigler, P.; Kozisek, M.; Rezacova, P.; Brynda, J.; Otwinowski, Z.; Pokorna, J.; Plesek, J.; Gruner, B.; Doleckova-Maresova, L.; Masa, M.; Sedlacek, J.; Bodem, J.; Krausslich, H. G.; Kral, V.; Konvalinka, J. From nonpeptide toward noncarbon protease inhibitors: Metallacarboranes as specific and potent inhibitors of HIV protease Proc. Natl. Acad. Sci. U.S.A 2005, 102, 15394-15399 (Pubitemid 41528068)
35. Kozisek, M.; Cigler, P.; Lepsik, M.; Fanfrlik, J.; Rezacova, P.; Brynda, J.; Pokorna, J.; Plesek, J.; Gruner, B.; Grantz Saskova, K.; Vaclavikova, J.; Kral, V.; Konvalinka, J. Inorganic polyhedral metallacarborane inhibitors of HIV protease: A new approach to overcoming antiviral resistance J. Med. Chem. 2008, 51, 4839-4843
36. Rezacova, P.; Pokorna, J.; Brynda, J.; Kozisek, M.; Cigler, P.; Lepsik, M.; Fanfrlik, J.; Rezac, J.; Grantz Saskova, K.; Sieglova, I.; Plesek, J.; Sicha, V.; Gruner, M.; Oberwinkler, H.; Sedlacek, J.; Krausslich, H. G.; Hobza, P.; Kral, V.; Konvalinka, J. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes J. Med. Chem. 2009, 52, 7132-7141
37. Ban, H. S.; Minegishi, H.; Shimizu, K.; Maruyama, M.; Yasui, Y.; Nakamura, H. Discovery of carboranes as inducers of 20S proteasome activity ChemMedChem 2010, 5, 1236-1241
38. Bednarska, K.; Olejniczak, A. B.; Wojtczak, B. A.; Sułowska, Z.; Lesnikowski, Z. J. Adenosine and 2′-deoxyadenosine modified with boron cluster pharmacophores as new classes of human blood platelet function modulators ChemMedChem 2010, 5, 749-756
39. Shoichet, B. K. Virtual screening of chemical libraries Nature 2004, 432, 862-865 (Pubitemid 40037142)
40. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications Nat. Rev. Drug Discovery 2004, 3, 935-949 (Pubitemid 39529931)
41. Klebe, G. Virtual ligand screening: Strategies, perspectives and limitations Drug Discovery Today 2006, 11, 580-594
42. Jorgensen, W. L. Efficient drug lead discovery and optimization Acc. Chem. Res. 2009, 42, 724-733
43. Chen, Y. Z.; Zhi, D. G. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule Proteins 2001, 43, 217-226
44. Paul, N.; Kellenberger, E.; Bret, G.; Muller, P.; Rognan, D. Recovering the true targets of specific ligands by virtual screening of the Protein Data Bank Proteins 2004, 54, 671-680 (Pubitemid 38298786)
45. Muller, P.; Lena, G.; Boilard, E.; Bezzine, S.; Lambeau, G.; Guichard, G.; Rognan, D. In silico -guided target identification of a scaffold-focused library: 1,3,5-Triazepan-2,6-diones as novel phospholipase A2 inhibitors J. Med. Chem. 2006, 49, 6768-6778 (Pubitemid 44749744)
46. 60 ACS Nano 2010, 4, 2283-2299
47. Calvaresi, M.; Zerbetto, F. Fullerene sorting proteins Nanoscale 2011, 3, 2873-2881
48. Gao, Z.; Li, H.; Zhang, H.; Liu, X.; Kang, L.; Luo, X.; Zhu, W.; Chen, K.; Wang, X.; Jiang, H. PDTD: A web-accessible protein database for drug target identification BMC Bioinf. 2008, 9, 104
49. Kellenberger, E.; Rodrigo, J.; Muller, P.; Rognan, D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy Proteins 2004, 57, 225-242 (Pubitemid 39223729)
50. Greene, G. L.; Gilna, P.; Waterfield, M.; Baker, A.; Hort, Y.; Shine, J. Sequence and expression of human estrogen receptor complementary DNA Science 1986, 231, 1150-1154 (Pubitemid 16016313)
51. Riggs, B. L.; Hartmann, L. C. Selective estrogen-receptor modulators-Mechanisms of action and application to clinical practice N. Engl. J. Med. 2003, 348, 618-629 (Pubitemid 36210865)
52. Leduc, A.-M.; Trent, J. O.; Wittliff, J. L.; Bramlett, K. S.; Briggs, S. L.; Chirgadze, N. Y.; Wang, Y.; Burris, T. P.; Spatola, A. F. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions Proc. Natl. Acad. Sci. U.S.A 2003, 100, 11272-11278
53. Pike, A. C. W.; Brzozowski, A. M.; Walton, J.; Hubbard, R. E.; Thorsell, A. G.; Li, Y. L.; Gustafsson, J.-Å; Carlquist, M. Structural insights into the mode of action of a pure antiestrogen Structure 2001, 9, 145-153 (Pubitemid 32215278)
54. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 1998, 95, 927-937 (Pubitemid 29019045)
55. Jordan, V. C. Tamoxifen: A most unlikely pioneering medicine Nat. Drug Rev. 2003, 2, 205-213 (Pubitemid 37361665)
56. Lee, H.-J.; Chang, C. Recent advances in androgen receptor action Cell. Mol. Life Sci. 2003, 60, 1613-1622 (Pubitemid 37041360)
57. Mooradian, A. D.; Morley, J. E.; Korenman, S. G. Biological actions of androgens Endocr. Rev. 1987, 8, 1-28
58. Zhi, L.; Martinborough, E. Selective androgen receptor modulators (SARMs) Annu. Rep. Med. Chem. 2001, 36, 169-180 (Pubitemid 33804597)
59. Sporn, M. B.; Roberts, A. B.; Goodman, D. S. The Retinoids, 2 nd ed.; Raven: New York, 1994.
60. Kastner, P.; Mark, M.; Chambon, P. Nonsteroid nuclear receptors: What are genetic studies telling us about their role in real life? Cell 1995, 83, 859-869 (Pubitemid 26006528)
61. Renaud, J.-P.; Rochel, N.; Ruff, M.; Vivat, V.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the RAR-γ ligand-binding domain bound to all- trans retinoic acid Nature 1995, 378, 681-689
62. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M. Structural determinants of ligand binding selectivity between the peroxisome proliferator activated receptors Proc. Natl. Acad. Sci. U.S.A 2001, 98, 13919-13924 (Pubitemid 33115999)
63. Peterson, S. A.; Klaubunde, T.; Lashuel, H. A.; Purkey, H.; Sacchettini, J. C.; Kelly, J. W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12956-12960 (Pubitemid 28509505)
64. Adamski-Werner, S. L.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis J. Med. Chem. 2004, 47, 355-374 (Pubitemid 38057880)
65. Johnson, S. M.; Wiseman, R. L.; Sekijima, Y.; Green, N. S.; Adamski-Werner, S. L.; Kelly, J. M. Native State Kinetic Stabilization as a Strategy To Ameliorate Protein Misfolding Diseases: A Focus on the Transthyretin Amyloidoses Acc. Chem. Res. 2005, 38, 911-921
66. Li, H.; Gao, Z.; Kang, L.; Zhang, H.; Yang, K.; Yu, K.; Luo, X.; Zhu, W.; Chen, K.; Shen, J.; Wang, X.; Jiang, H. TarFisDock: A web server for identifying drug targets with docking approach Nucleic Acids Res. 2006, 34, W219-W224
67. Tang, J.; Yu, C. L.; Williams, S. R.; Springman, E.; Jeffery, D.; Sprengeler, P. A.; Estevez, A.; Sampang, J.; Shrader, W.; Spencer, J.; Young, W.; McGrath, M.; Katz, B. A. Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein J. Biol. Chem. 2005, 280, 41077-41089 (Pubitemid 41780603)
68. Hedstrom, L. Serine protease mechanism and specificity Chem. Rev. 2002, 102, 4501-4523
69. Dobritzsch, D.; Schneider, G.; Schnackerz, K. D.; Lindqvist, Y. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil EMBO J. 2001, 20, 650-660 (Pubitemid 32167630)
70. Johnson, D.; Dean, D. R.; Smith, A. D.; Johnson, M. K. Structure, function and formation of biological iron-sulfur clusters Annu. Rev. Biochem. 2005, 74, 247-281 (Pubitemid 40995508)
71. Blow, D. M. Structure and mechanism of chymotrypsin Acc. Chem. Res. 1976, 9, 145-152
72. Yennawar, H. P.; Yennawar, N. H.; Farber, G. K. A structural explanation for enzyme memory in nonaqueous solvents J. Am. Chem. Soc. 1995, 117, 577-585
73. Zagotta, W. N.; Olivier, N. B.; Black, K. D.; Young, E. C.; Olson, R.; Gouaux, E. Structural basis for modulation and agonist specificity of HCN pacemaker channels Nature 2003, 425, 200-205 (Pubitemid 37150901)
74. Chen, S.; Wang, J.; Siegelbaum, S. A. Properties of hyperpolarization- activated pacemaker current defined by coassembly of HCN1 and HCN2 subunits and basal modulation by cyclic nucleotide J. Gen. Physiol. 2001, 117, 491-504
75. Olejniczak, A. B.; Semenuk, A.; Kwiatkowski, M.; Lesnikowski, Z. J. Synthesis of adenosine containing carborane modification J. Organomet. Chem. 2003, 680, 124-126
76. Baruscotti, M.; Bucchi, A.; DiFrancesco, D. Physiology and pharmacology of the cardiac pacemaker ("funny") current Pharmacol. Therapeut. 2005, 107, 59-79 (Pubitemid 40800408)
77. Gal, P.; Harmat, V.; Kocsis, A.; Bian, T.; Barna, L.; Ambrus, G.; Vegh, B.; Balczer, J.; Sim, R. B.; Naray-Szabo, G.; Zavodszky, P. A true autoactivating enzyme. Structural insight into mannose-binding lectin-associated serine protease-2 activations J. Biol. Chem. 2005, 280, 33435-33444 (Pubitemid 41397142)
78. Morley, B. J.; Walport, M. J. The Complement FactsBook; Academic Press: London, 1999.
79. Rawlings, N. D.; Barrett, A. J.; Bateman, A. MEROPS: The peptidase database Nucleic Acids Res. 2010, 38, D227-D233
80. Hooper, N. M. Proteases in Biology and Medicine; Portland Press: London, 2002.
81. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: Current status and future prospects J. Med. Chem. 2000, 43, 305-341 (Pubitemid 30102072)
82. Noble, M. E. M.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: Insights into drug design from structure Science 2004, 303, 1800-1805 (Pubitemid 38374863)
83. Fitzgerald, G. A. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease Nat. Rev. Drug Discovery 2003, 2, 879-890
84. Roth, S. Y.; Denu, J. M.; Allis, C. D. Histone acetyltransferases Annu. Rev. Biochem. 2001, 70, 81-120 (Pubitemid 32662206)
85. Berman, E. M.; Werbel, L. M. The renewed potential for folate antagonists in contemporary cancer chemotherapy J. Med. Chem. 1991, 34, 479-485
86. Hawser, S.; Lociuro, S.; Islam, K. Dihydrofolate reductase inhibitors as antibacterial agents Biochem. Pharmacol. 2006, 71, 941-948
87. Cao, W.; Matherly, L. H. Structural determinants of folate and antifolate membrane transport by the reduced folate carrier. In Drug Metabolism and Transport; Lash, L. H., Ed.; Humana Press: Totowa, NJ, 2005; pp 291-318.
88. Assaraf, Y. G. Molecular Basis of Antifolate Resistance Cancer Metastasis Rev. 2007, 26, 153-181 (Pubitemid 46452189)
89. Waldmann, T. A. Monoclonal antibodies in diagnosis and therapy Science 1991, 252, 1657-1662 (Pubitemid 21917082)
90. Pak, R. H.; Primus, F. J.; Rickard-Dickson, K. J.; Ng, L. L.; Kane, R. R.; Hawthorne, M. F. Preparation and properties of nido -carborane-specific monoclonal antibodies for potential use in boron neutron capture therapy for cancer Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 6986-6990
91. Primus, F. J.; Pak, R. H.; Rickard-Dickson, K. J.; Szalai, G.; Bolen, J. L., Jr.; Kane, R. R.; Hawthorne., M. F. Bispecific antibody mediated targeting of nido -carboranes to human colon carcinoma cells Bioconjugate Chem. 1996, 7, 532-535 (Pubitemid 26369614)
92. Tatham, A. T.; Nakamura, H.; Wiener, E. C.; Yamamoto, J. Relaxation properties of a dual-labeled probe for MRI and neutron capture therapy Magn. Reson. Med. 1999, 42, 32-36 (Pubitemid 29325610)
93. Schneidman-Duhovny, D.; Inbar, Y.; Polak, V.; Shatsky, M.; Halperin, I.; Benyamini, H.; Barzilai, A.; Dror, O.; Haspel, N.; Nussinov, R.; Wolfson, H. J. Taking geometry to its edge: Fast unbound rigid (and hinge-bent) docking Proteins 2003, 52, 107-112 (Pubitemid 36648858)
94. Zhang, C.; Vasmatzis, G.; Cornette, J. L.; DeLisi, C. Determination of atomic desolvation energies from the structures of crystallized proteins J. Mol. Biol. 1997, 267, 707-726 (Pubitemid 27170692)
95. Andrusier, N.; Nussinov, R.; Wolfson, H. J. FireDock: Fast interaction refinement in molecular docking Proteins 2007, 69, 139-159 (Pubitemid 47339146)
96. Kingsford, C. L.; Chazelle, B.; Singh, M. Solving and analyzing side-chain positioning problems using linear and integer programming Bioinformatics 2005, 21, 1028-1036 (Pubitemid 40467925)
97. Gray, J. J.; Moughon, S.; Wang, C.; Schueler-Furman, O.; Kuhlman, B.; Rohl, C. A.; Baker, D. Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations J. Mol. Biol. 2003, 331, 281-299 (Pubitemid 36870793)
98. Neria, E.; Fischer, S.; Karplus, M. Simulation of activation free energies in molecular systems J. Chem. Phys. 1996, 105, 1902-1921 (Pubitemid 126612899)
99. Tiwari, R.; Mahasenan, K.; Pavlovicz, R.; Li, C.; Tjarks, W. Carborane clusters in computational drug design: A comparative docking evaluation using AutoDock, FlexX, Glide, and Surflex J. Chem. Inf. Model. 2009, 49, 1581-1589
100. Bandyopadhyaya, A. K.; Tiwari, R.; Tjarks, W. Comparative molecular field analysis and comparative molecular similarity indices analysis of boron-containing human thymidine kinase 1 substrates Bioorg. Med. Chem. 2006, 14, 6924-6932 (Pubitemid 44307649)
101. Johnsamuel, J.; Byun, Y.; Jones, T. P.; Endo, Y.; Tjarks, W. A new strategy for molecular modeling and receptor-based design of carborane containing compounds J. Organomet. Chem. 2003, 680, 223-231
102. Martichonok, V.; Jones, J. B. Cysteine proteases such as papain are not inhibited by substrate analogue peptidyl boronic acids Bioorg. Med. Chem. 1997, 5, 679-684 (Pubitemid 27199392)
103. Minkkila, A.; Saario, S. M.; Kasnanen, H.; Leppanen, J.; Poso, A.; Nevalainen, T. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase J. Med. Chem. 2008, 51, 7057-7060
104. 10B-enriched 3-[5-{2-(2,3-dihydroxyprop-1-yl)- o -carboran-1-yl}pentan-1-yl]thymidine (N5-2OH), a new boron delivery agent for boron neutron capture therapy of brain tumors J. Med. Chem. 2006, 49, 5513-5523 (Pubitemid 44373182)
105. Narayanasamy, S.; Thirumamagal, B. T.; Johnsamuel, J.; Byun, Y.; Al-Madhoun, A. S.; Usova, E.; Cosquer, G. Y.; Yan, J.; Bandyopadhyaya, A. K.; Tiwari, R.; Eriksson, S.; Tjarks, W. Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer Bioorg. Med. Chem. 2006, 14, 6886-6899 (Pubitemid 44307655)
106. Janin, J.; Henrick, K.; Moult, J.; Eyck, L. T.; Sternberg, M. J. E.; Vajda, S.; Vakser, I.; Wodak, S. J. CAPRI: A Critical Assessment of PRedicted Interactions Proteins 2003, 52, 2-9 (Pubitemid 36648842)